Gilead Sciences, Inc. (NASDAQ:GILD) Shares Purchased by Fortem Financial Group LLC

Fortem Financial Group LLC grew its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 6.5% during the fourth quarter, Holdings Channel reports. The firm owned 6,670 shares of the biopharmaceutical company’s stock after purchasing an additional 407 shares during the period. Fortem Financial Group LLC’s holdings in Gilead Sciences were worth $616,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of GILD. Bellevue Group AG lifted its position in Gilead Sciences by 18.2% in the third quarter. Bellevue Group AG now owns 46,027 shares of the biopharmaceutical company’s stock valued at $3,859,000 after acquiring an additional 7,093 shares during the last quarter. Quantinno Capital Management LP lifted its holdings in shares of Gilead Sciences by 149.5% in the 3rd quarter. Quantinno Capital Management LP now owns 81,620 shares of the biopharmaceutical company’s stock valued at $6,843,000 after purchasing an additional 48,910 shares during the last quarter. Legal & General Group Plc boosted its position in shares of Gilead Sciences by 0.8% in the 2nd quarter. Legal & General Group Plc now owns 12,414,268 shares of the biopharmaceutical company’s stock valued at $851,743,000 after purchasing an additional 93,068 shares during the period. IRON Financial LLC acquired a new stake in shares of Gilead Sciences in the 3rd quarter valued at about $830,000. Finally, Wealth Enhancement Advisory Services LLC grew its stake in Gilead Sciences by 12.9% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 323,011 shares of the biopharmaceutical company’s stock worth $27,081,000 after buying an additional 36,895 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on GILD. Wells Fargo & Company increased their price objective on Gilead Sciences from $100.00 to $105.00 and gave the company an “overweight” rating in a report on Thursday, November 7th. Cantor Fitzgerald reissued a “neutral” rating and set a $80.00 price objective on shares of Gilead Sciences in a research report on Wednesday, December 11th. UBS Group upped their target price on shares of Gilead Sciences from $70.00 to $96.00 and gave the company a “neutral” rating in a report on Thursday, November 21st. Leerink Partnrs raised Gilead Sciences from a “hold” rating to a “strong-buy” rating in a report on Monday, October 21st. Finally, Royal Bank of Canada reaffirmed a “sector perform” rating and set a $84.00 price objective on shares of Gilead Sciences in a research note on Wednesday, December 11th. Twelve equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and four have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $96.43.

Gilead Sciences Price Performance

Shares of GILD stock traded down $0.35 during mid-day trading on Monday, reaching $91.06. The stock had a trading volume of 4,103,792 shares, compared to its average volume of 3,856,787. The company has a market cap of $113.48 billion, a P/E ratio of 1,011.78, a price-to-earnings-growth ratio of 2.24 and a beta of 0.18. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a 12-month low of $62.07 and a 12-month high of $98.90. The business has a 50-day simple moving average of $91.81 and a 200 day simple moving average of $82.68.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, topping the consensus estimate of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The company had revenue of $7.55 billion during the quarter, compared to the consensus estimate of $7.01 billion. During the same quarter last year, the business posted $2.29 earnings per share. Gilead Sciences’s revenue was up 7.0% compared to the same quarter last year. On average, sell-side analysts anticipate that Gilead Sciences, Inc. will post 4.36 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, December 30th. Investors of record on Friday, December 13th were given a dividend of $0.77 per share. The ex-dividend date of this dividend was Friday, December 13th. This represents a $3.08 dividend on an annualized basis and a yield of 3.38%. Gilead Sciences’s dividend payout ratio (DPR) is currently 3,422.22%.

Insiders Place Their Bets

In related news, Director Jeffrey Bluestone sold 6,788 shares of the business’s stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $91.39, for a total value of $620,355.32. Following the completion of the sale, the director now directly owns 8,920 shares in the company, valued at approximately $815,198.80. The trade was a 43.21 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Andrew D. Dickinson sold 8,500 shares of the stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $91.96, for a total transaction of $781,660.00. Following the transaction, the chief financial officer now directly owns 132,373 shares in the company, valued at approximately $12,173,021.08. This represents a 6.03 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 453,734 shares of company stock valued at $41,902,086. Company insiders own 0.16% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.